# US 2018/0024152 A1 · Hdl-associated protein biomarker panel detection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0024152 A1
- Document ID: US20180024152A1
- Status: Published application
- Kind: A1
- Application number: 15/656,592
- Filed: 2017-07-21
- Published: 2018-01-25
- Earliest claimed: 2016-07-21
- Assignees: Cleveland Heartlab, Inc.
- Applicants: Cleveland HeartLab, Inc.
- Inventors: Cory Bystrom; Timothy Collier
- Web page: https://patentgrep.com/patent/US20180024152A1

## CPC

- G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)}
- G01N 2333/775: Apolipopeptides
- G01N 2560/00: Chemical aspects of mass spectrometric analysis of biological material
- G01N 2570/00: Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
- G01N 2800/32: Cardiovascular disorders
- G01N 2800/324: Coronary artery diseases, e.g. angina pectoris, myocardial infarction
- G01N 2800/50: Determining the risk of developing a disease
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided herein are methods, systems, and compositions for detecting one or more HDL-associated proteins (e.g., ApoC3; ApoC3 and ApoA1; ApoC3 and SAA1/2; or proteins in Biomarker Panels 1-30) in a sample from a subject with, or suspected of having, cardiovascular disease (CVD) or other HDL related disease. In certain embodiments, such methods, systems, and compositions are used to determine the approximate risk of CVD (or other disease) for a subject, and/or the approximate cholesterol efflux capacity (CEC) of a sample.

## Claims

### Claim 1

A method comprising: detecting the level of at least one HDL-associated protein in a sample from a subject, wherein said at least one HDL-associated protein comprises ApoC3, and wherein said subject has, or is suspected of having, cardiovascular disease.

### Claim 2 (depends on 1)

The method of claim 1, wherein said sample is a purified high-density lipoprotein sample.

### Claim 3 (depends on 1)

The method of claim 1, wherein said sample is selected from the group consisting of: a serum sample, a plasma sample, and a blood sample.

### Claim 4 (depends on 1)

The method of claim 1, further comprising: normalizing said level of said at least one HDL-associated protein to said approximate level of total HDL particles or ApoA1 or HDL-cholesterol to generate at least one normalized HDL protein value.

### Claim 5 (depends on 4)

The method of claim 4, wherein said determining the approximate level of total HDL particles or ApoA1 or HDL-cholesterol in said sample comprises determining the level of an internal standard added to said sample, wherein said internal standard comprises a labeled HDL protein.

### Claim 6 (depends on 1)

The method of claim 1, wherein said detecting the level of at least one HDL protein comprises adding a reagent to said sample, wherein said reagent digests HDL proteins in said sample.

### Claim 7 (depends on 1)

The method of claim 1, wherein said detecting the level of at least one HDL-associated protein comprises performing an assay on a least a portion of said sample that detects ApoC3 or a fragment of ApoC3.

### Claim 8 (depends on 7)

The method of claim 7, wherein said assay is a mass spectrometry assay or immunoassay.

### Claim 9 (depends on 1)

The method of claim 1, wherein said at least one HDL-associated protein further comprises Apolipoprotein A1 (ApoA1).

### Claim 10 (depends on 9)

The method of claim 9, wherein said detecting the level of at least one HDL protein comprises performing an assay that detects: i) ApoC3, or fragment of ApoC3, and ii) ApoA1, or a fragment of ApoA1.

### Claim 11 (depends on 1)

The method of claim 1, wherein said at least one HDL-associated protein further comprises Apolipoprotein C1 (ApoC1).

### Claim 12 (depends on 11)

The method of claim 11, wherein said detecting the level of at least one HDL-associated protein comprises performing an assay that detects: i) ApoC3, or fragment of ApoC3, and ii) ApoC1, or a fragment of ApoC1.

### Claim 13 (depends on 1)

The method of claim 1, wherein said at least one HDL-associated protein further comprises Apolipoprotein C2 (ApoC2).

### Claim 14 (depends on 13)

The method of claim 13, wherein said detecting the level of at least one HDL-associated protein comprises performing an assay that detects: i) ApoC3, or fragment of ApoC3, and ii) ApoC2, or a fragment of ApoC2.

### Claim 15

A system or composition comprising:
a) a sample from a subject with, or suspected of having, cardiovascular disease; and
b) a first component, wherein said first component comprises:
i) an Apolipoprotein C3 (ApoC3) binding agent, and/or
ii) a ApoC3 mass spectrometry standard.

### Claim 16 (depends on 15)

The system or composition of claim 15, further comprising: c) a second component comprising a composition comprising detectably labeled HDL protein that can serve as a calibrator for normalizing signal in said sample to the approximate level of total HDL particles, ApoA1, or HDL-cholesterol present in said sample.

### Claim 17 (depends on 15)

The system or composition of claim 15, wherein said sample is selected from the group consisting of: a serum sample, a plasma sample, a blood sample, and a purified high-density lipoprotein (HDL) sample.

### Claim 18 (depends on 15)

The system or composition of claim 15, further comprising: c) a second component comprising: i) an apolipoprotein A1 (ApoA1) binding agent, and/or ii) an ApoA1 mass spectrometry standard.

### Claim 19 (depends on 15)

The system or composition of claim 15, further comprising: c) a second component comprising: i) an apolipoprotein C1 (ApoC1) binding agent, and/or ii) an ApoC1 mass spectrometry standard.

### Claim 20 (depends on 15)

The system or composition of claim 15, further comprising: c) a second component comprising: i) an apolipoprotein C2 (ApoC2) binding agent, and/or ii) an ApoC2 mass spectrometry standard.

### Claim 21

A method of determining the approximate risk of cardiovascular disease and/or approximate reverse cholesterol transport capacity comprising:
a) detecting, in a sample from a subject, the level of each of the HDL-associated proteins in Biomarker Panels 17, 18 and/or 19,
wherein said Biomarker Panel 17 comprises proteins: ApoC1, ApoC2, and ApoC3;
wherein said Biomarker Panel 18 comprises proteins: ApoA1, ApoC1, ApoC2, ApoC3, and ApoC4, and
wherein said Biomarker Panel comprises proteins: ApoA2, ApoC1, ApoC2, ApoC3, ApoD, and SAA1/2; and
b) determining the approximate risk of cardiovascular disease (CVD) for said subject, and/or the approximate cholesterol efflux capacity (CEC) of said sample.

### Claim 22 (depends on 21)

The method of claim 21, wherein said sample is selected from the group consisting of: a serum sample, a plasma sample, a blood sample, and a purified high-density lipoprotein (HDL) sample.

### Claim 23 (depends on 21)

The method of claim 21, wherein said determining comprises employing a first algorithm to generate a cardiovascular disease (CVD) risk score or cholesterol efflux capacity (CEC) score, wherein said first algorithm performs operations comprising: i) multiplying each HDL-associated protein level by a predetermined coefficient to generate multiplied values, and ii) adding said multiplied values together, plus a panel-specific constant value, thereby generating said CVD risk score or said CEC score.

### Claim 24 (depends on 21)

The method of claim 21, further comprising: c) generating a report that provides said CVD risk score and/or said CEC score.
